amifostine
Trade name: ethyol
Approved
Dec 8, 1995
Amifostine is an organic thiophosphate cytoprotective agent known chemically as 2-[(3¬ aminopropyl)amino]ethanethiol dihydrogen phosphate (ester), it’s adjuvant used in cancer chemotherapy and radiotherapy involving DNA-binding chemotherapeutic agents. It is marketed under the trade name Ethyol. Amifostine is a prodrug and is dephosphorylated by alkaline phosphatase in tissues to a pharmacologically active free thiol metabolite. This metabolite is believed to be responsible for the reduction of the cumulative renal toxicity of cisplatin and for the reduction of the toxic effects of radiation on normal oral tissues. The ability of Ethyol to differentially protect normal tissues is attributed to the higher capillary alkaline phosphatase activity, higher pH and better vascularity of normal tissues relative to tumor tissue, which results in a more rapid generation of the active thiol metabolite as well as a higher rate constant for uptake into cells. The higher concentration of the thiol metabolite in normal tissues is available to bind to, and thereby detoxify, reactive metabolites of cisplatin. This thiol metabolite can also scavenge reactive oxygen species generated by exposure to either cisplatin or radiation. Healthy cells are preferentially protected because amifostine and metabolites are present in healthy cells at 100-fold greater concentrations than in tumor cells. — NCATS
Clinical trial activity
81 trials · 75 clinical orgs · 8 marketing orgs
Earliest trial started May 1, 1988 (NCT00003582)
Timeline
1980s
- Jan 1, 1988
Earliest Phase 1 Sponsor(trial)
1990s
- May 30, 1990
Orphan Drug Designation
- Jan 1, 1995
Earliest Phase 2 Sponsor(trial)
- Dec 8, 1995
US Bioscience — Earliest FDA Approval
- Dec 8, 1995
Clinigen — Marketing Organization
- Dec 8, 1995
Cosette — Marketing Organization
- Dec 8, 1995
Clinigene International Ltd — NDA Secondary Org
- Dec 8, 1995
US Bioscience — NDA Organization
- Dec 8, 1995
Clinigen — NDA Secondary Org
- Dec 8, 1995
LEGACY PHARMA — Marketing Organization
- Jan 1, 1998
Earliest Phase 3 Sponsor(trial)
2000s
- Mar 14, 2008
Sun Pharmaceuticals — Marketing Organization
2010s
- Jul 17, 2017
Eugia Pharma — Marketing Organization
- Jul 17, 2017
Mylan — Marketing Organization
Indications
Studied for
- Acute Radiation Syndrome · Phase 1
- Anemia · Phase 2
- Bone Marrow Diseases · Phase 2
- Brain Neoplasms · Phase 2
- Breast Neoplasms · Phase 2
- Carcinoma · Phase 2
- Carcinoma, Non-Small-Cell Lung · Phase 2
- Carcinoma, Renal Cell · Phase 1
- Carcinoma, Squamous Cell · Phase 3
- Chordoma · Phase 1
- Colorectal Neoplasms · Phase 2
- Deglutition Disorders · Phase 2
- Drug-Related Side Effects and Adverse Reactions · Phase 4
- Endometrial Neoplasms · Phase 2
- Esophagitis · Phase 2
- Fallopian Tube Neoplasms · Phase 2
- Fanconi Anemia · Phase 1
- Gestational Trophoblastic Disease · Phase 3
- Hamartoma · Phase 2
- Head and Neck Neoplasms · Phase 4
- Hepatoblastoma · Phase 3
- Hodgkin Disease · Phase 2
- Kidney Neoplasms · Phase 2
- Leukemia · Phase 2
- Leukemia, Myeloid, Acute · Phase 1/Phase 2
- Liver Neoplasms · Phase 3
- Lung Neoplasms · Phase 4
- Lymphoma · Phase 4
- Lymphoma, Non-Hodgkin · Phase 2
- Lymphoma, T-Cell · Phase 1/Phase 2
- Melanoma · Phase 1
- Mesothelioma, Malignant · Phase 1
- Mucositis · Phase 2
- Multiple Myeloma · Phase 3
- Myelodysplastic Syndromes · Phase 2
- Myeloproliferative Disorders · Phase 2
- Nasopharyngeal Carcinoma · Phase 3
- Nasopharyngeal Neoplasms · Phase 3
- Neoplasms · Phase 4
- Neuroblastoma · Phase 1/Phase 2
- Neutropenia · Phase 2
- Ovarian Neoplasms · Phase 3
- Peripheral Nervous System Diseases · Phase 3
- Pneumonia · Phase 2
- Precancerous Conditions · Phase 1
- Prostatic Neoplasms · Phase 2
- Quality of Life · Phase 3
- Radiodermatitis · Phase 2
- Rectal Neoplasms · Phase 2
- Retinoblastoma · Phase 1
- Salivary Gland Diseases · Phase 2
- Sarcoma · Phase 2
- Stomatitis · Phase 4
- Testicular Neoplasms · Phase 2
- Trigeminal Neuralgia · Phase 3
- Urinary Bladder Neoplasms · Phase 2
- Uterine Cervical Neoplasms · Phase 2
- Xerostomia · Phase 2
Mechanism of action
- Unspecified targetOTHER
Reactive metabolite scavenging agent
Prodrug. Scavenge of reactive oxygen species and reactive metabolites of cisplatin
- Unspecified targetAntioxidant
Antioxidant
Prodrug. Scavenge of reactive oxygen species and reactive metabolites of cisplatin
Approval history
- approvedPriority reviewDec 8, 1995
Chemistry & pharmacology
SMILES
NCCCNCCSP(O)(O)=O- Mol. weight
- 214.223 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
- Delivery
- Parenteral
- Availability
- Discontinued
Oral
No
Parenteral
Yes
Topical
No
Sources
- WikipediaAmifostine ↗
- NCATSILA426L95O ↗
- ChEMBLCHEMBL1006 ↗
Also known as
- amifostina
- amifostina
- amifostine
- amifostine
- amifostine
- amifostine
- amifostine
- amifostine
- amifostine
- amifostine
- amifostine
- amifostine
- amifostine
- amifostine trihydrate
- amifostine trihydrate
- amifostine trihydrate
- amifostinum
- amifostinum
- aminopropylaminoethyl thiophosphate
- aminopropylaminoethyl thiophosphate
- aminopropylaminoethyl thiophosphate
- ethiofos
- ethiofos
- ethiofos
- ethyol
- ethyol
- ethyol
- ethyol
- gammaphos
- gammaphos
- gammaphos
- radprotect
- wr-2721
- wr-2721
- wr-2721
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07192588 | Phase 2 | Jul 26, 2024 | EXCELYA, Graegis Pharmaceuticals Ltd |
| NCT05230680 | Phase 1/Phase 2 (Phase 2) | May 1, 2022 | Sungkyunkwan University |
| NCT03702985 | Phase 2 | May 28, 2018 | Fudan University |
| NCT02587442 | Phase 1 | Oct 1, 2015 | Original BioMedicals Co. Ltd. |
| NCT01998529 | Phase 1 | Aug 1, 2014 | University of Texas at Houston |
| NCT01762514 | Phase 2 | Jan 1, 2013 | Dalian Merro Pharmaceutical Co. Ltd, Sun Yat-Sen University |
| NCT01586117 | Phase 2 | Feb 1, 2012 | Chinese Academy of Medical Sciences |
| NCT01288625 | Phase 4 | Mar 1, 2011 | People's Liberation Army of China, Sun Pharmaceuticals |
| NCT05167370 | Phase 2 | Dec 13, 2010 | Good Samaritan Hospital, Cincinnati, University of Cincinnati |
| NCT01364259 | Phase 3 | Sep 1, 2008 | Stanford University |
| NCT00571298 | Phase 1 | Nov 1, 2007 | Harvard University |
| NCT00409331 | Phase 2 | Dec 1, 2006 | MedImmune, University of Texas at Houston |
| NCT00601198 | Phase 2 | Oct 1, 2006 | AstraZeneca, MedImmune, University of Cincinnati |
| NCT00274937 | Phase 3 | Feb 1, 2006 | National Cancer Institute (NCI) |
| NCT00503776 | Phase 2 | Jan 1, 2006 | National Cancer Institute (NCI), Vanderbilt University |
| NCT00137358 | Phase 1 | Aug 26, 2005 | MedImmune, University of Alabama, Birmingham |
| NCT00217438 | Phase 3 | Jul 1, 2005 | National Cancer Institute (NCI), University of Washington |
| NCT00217542 | Phase 1 | Jul 1, 2005 | National Cancer Institute (NCI), Yale University |
| NCT00098683 | Phase 2 | Jan 1, 2005 | Johns Hopkins University, National Cancer Institute (NCI), University of New Mexico |
| NCT00086099 | Phase 1/Phase 2 (Phase 2) | Jul 1, 2004 | MedImmune |
Organizations
Research & Development (75)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Government | 34 | 9 | 4 | 1995 |
| MedImmune | For profit | 10 | 2 | 4 | 2002 |
| Harvard University | Academic/Hospital | 6 | 6 | 2 | 1998 |
| University of Texas at Houston | Academic/Hospital | 4 | 4 | 2 | 1997 |
| Rush University | Academic/Hospital | 3 | 3 | 2 | 1997 |
| University of Arizona | Academic/Hospital | 3 | 3 | 1 | 1997 |
| Alza | For profit | 2 | 1 | 1 | 1997 |
| AstraZeneca | For profit | 2 | 0 | 1 | 2003 |
| City of Hope National Medical Center | Academic/Hospital | 2 | 1 | 2 | 1999 |
| European Organisation for Research and Treatment of Cancer | Academic/Hospital | 2 | 2 | 1 | 1998 |
| Gynecologic Oncology Group | Academic/Hospital | 2 | 2 | 2 | 1998 |
| Mayo Clinic | Academic/Hospital | 2 | 0 | 2 | 2001 |
| Northwestern University | Academic/Hospital | 2 | 1 | 2 | 1999 |
| Radiation Therapy Oncology Group | Academic/Hospital | 2 | 2 | 2 | 1998 |
| Stanford University | Academic/Hospital | 2 | 1 | 2 | 2000 |
| Thomas Jefferson University | Academic/Hospital | 2 | 2 | 2 | 1997 |
| University of Alabama, Birmingham | Academic/Hospital | 2 | 2 | 2 | 2002 |
| University of California, Los Angeles | Academic/Hospital | 2 | 2 | 1 | 1997 |
| University of Chicago | Academic/Hospital | 2 | 2 | 1 | 1996 |
| University of Cincinnati | Academic/Hospital | 2 | 2 | 1 | 2006 |
Marketing (10)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Clinigen | For profit | MKTG | Dec 8, 1995 |
| Clinigen | For profit | NDA2 | Dec 8, 1995 |
| Clinigene International Ltd | For profit | NDA2 | Dec 8, 1995 |
| Cosette | For profit | MKTG | Dec 8, 1995 |
| Eugia Pharma | For profit | MKTG | Jul 17, 2017 |
| LEGACY PHARMA | For profit | MKTG | Dec 8, 1995 |
| Mylan | For profit | MKTG | Jul 17, 2017 |
| Sun Pharmaceuticals | For profit | MKTG | Mar 14, 2008 |
| Sun Pharmaceuticals | For profit | SYN | Mar 14, 2008 |
| US Bioscience | For profit | NDA | Dec 8, 1995 |